Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.70 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115030 | 0.88 | MCHR1 (1.00) | MCHR1POLBSIGMAR1KCNH2 | |
| SCHEMBL5129340 | 0.88 | MCHR1 (1.00) | MCHR1POLBSIGMAR1KCNH2 | |
| SCHEMBL5129107 | 0.87 | MCHR1 (0.87) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 | |
| SCHEMBL5129379 | 0.86 | MCHR1 (1.00) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 | |
| SCHEMBL17946047 | 0.86 | POLB (0.91) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 | |
| SCHEMBL5116487 | 0.86 | MCHR1 (0.93) | MCHR1POLBKCNH2 | |
| SCHEMBL6509291 | 0.86 | CCR8 (0.82) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 | |
| SCHEMBL5129225 | 0.85 | MCHR1 (0.81) | MCHR1POLBKCNH2 | |
| SCHEMBL24514563 | 0.84 | POLB (0.86) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 | |
| SCHEMBL17950883 | 0.84 | ADIPOR2 (0.90) | MCHR1POLBSIGMAR1ADIPOR2ADIPOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | MCHR1 892/4885POLB 1635/4885SIGMAR1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.